Further evidence of the clinical utility of TET2 inhibitors was provided by Dominguez et al. [120], who observed growth inhibition of TET2‐knockdown DLBCL cells after treatment with a histone deacetylase 3 (HDAC3) inhibitor in vitro. Here, TET2 is linked to diffuse large B-cell lymphoma.